127 related articles for article (PubMed ID: 20023245)
1. HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer.
Lissoni P; Messina G; Rovelli F; Brivio F; Fumagalli L; Villa S; Bartolacelli E
In Vivo; 2009; 23(6):987-9. PubMed ID: 20023245
[TBL] [Abstract][Full Text] [Related]
2. A study of surgical psychoncology in breast cancer: perioperative variation of prolactin serum levels in women with operable breast cancer in relation to their maternal psychological behaviour.
Messina G; Lissoni P; Brivio F; Rovelli F; Fumagalli L; Bartolacelli E; Mazza U; Colombo E; Bertoglio A
In Vivo; 2008; 22(6):845-8. PubMed ID: 19181018
[TBL] [Abstract][Full Text] [Related]
3. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
[TBL] [Abstract][Full Text] [Related]
4. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
[TBL] [Abstract][Full Text] [Related]
5. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
6. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
7. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
[TBL] [Abstract][Full Text] [Related]
8. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
10. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
[TBL] [Abstract][Full Text] [Related]
12. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
14. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
15. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
[TBL] [Abstract][Full Text] [Related]
16. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
[TBL] [Abstract][Full Text] [Related]
17. Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients.
Mandalà M; Lissoni P; Ferretti G; Rocca A; Torri V; Moro C; Curigliano G; Barni S
Oncology; 2002; 63(4):370-7. PubMed ID: 12417792
[TBL] [Abstract][Full Text] [Related]
18. Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion.
Lissoni P; Barni S; Cazzaniga M; Ardizzoia A; Rovelli F; Tancini G; Brivio F; Frigerio F
Oncology; 1995; 52(6):439-42. PubMed ID: 7478427
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]